| Nov 15 |
Large pharmas, biotechs down as industries grapple with RFK Jr. at HHS
|
| Nov 15 |
Bristol Myers gets positive EMA opinion for repotrectinib
|
| Nov 15 |
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
|
| Nov 15 |
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
|
| Nov 14 |
Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug
|
| Nov 14 |
Tudor Investment adds Infinera, Trane, exits Disney, UnitedHealth, among top Q3 trades
|
| Nov 14 |
Bristol-Myers Squibb Company's (NYSE:BMY) high institutional ownership speaks for itself as stock continues to impress, up 5.7% over last week
|
| Nov 14 |
2 Beaten-Down Dividend Stocks to Buy and Hold
|
| Nov 13 |
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
|
| Nov 13 |
Is Bristol-Myers Squibb Company (BMY) Among The Top Dividend Contenders Right Now?
|
